Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer - Related Studies

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

This study has been completed.

Study NCT00001228. Last updated on September 7, 2007. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Islet Cell Adenoma
		Zollinger Ellison Syndrome

2	Additional conditions recognized in this trial
		Adenoma, Islet Cell
		Syndrome
		Zollinger-Ellison Syndrome

3	More general conditions related to this trial
		Adenoma
		Digestive System Diseases
		Digestive System Neoplasms
		Disease
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Intestinal Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Pancreatic Diseases
		Pancreatic Neoplasms
		Paraneoplastic Endocrine Syndromes
		Paraneoplastic Syndromes
		Pathologic Processes
		Peptic Ulcer
		Stomach Diseases

4	Interventions listed in this trial
		Interferon

5	Additional drug interventions recognized in this trial
		Interferon Alfa-2b
		Interferons

6	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Infective Agents
		Antineoplastic Agents
		Antiviral Agents
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)